0001209191-23-049999.txt : 20230919 0001209191-23-049999.hdr.sgml : 20230919 20230919170506 ACCESSION NUMBER: 0001209191-23-049999 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230918 FILED AS OF DATE: 20230919 DATE AS OF CHANGE: 20230919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fiedorek Fred T. CENTRAL INDEX KEY: 0001657185 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 231264584 MAIL ADDRESS: STREET 1: 55 BALDWIN LANE CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-18 0 0001840574 Verve Therapeutics, Inc. VERV 0001657185 Fiedorek Fred T. C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 0 1 0 0 Chief Medical Officer 0 Stock Option (right to buy) 12.71 2023-09-18 4 A 0 180000 0.00 A 2033-09-17 Common Stock 180000 180000 D The option was granted on September 18, 2023. 25% of the shares underlying the option will vest on September 18, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until September 18, 2027. /s/ Andrew Ashe, Attorney-in-Fact for Fred T. Fiedorek 2023-09-19